Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × afuresertib × Gynecologic × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1 Gynecologic 1

Conditions

Platinum-resistant Ovarian Cancer 1

Interventions

Paclitaxel 202 Carboplatin 195 Bevacizumab 122 Cisplatin 117 pembrolizumab 80 Gemcitabine 57 olaparib 49 Docetaxel 42 Topotecan 37 niraparib 34 Radiotherapy 34 Cyclophosphamide 32 Taxes 30 liposomal doxorubicin 28 Doxorubicin 26 Nivolumab 25 Letrozole 25 Drug Therapy 24 Oxaliplatin 20 Magnetic Resonance Spectroscopy 20 Albumin-Bound Paclitaxel 20 apatinib 19 Etoposide 19 durvalumab 18 dostarlimab 18 Brachytherapy 18 lenvatinib 17 Immunoglobulin G 17 Hyperthermic Intraperitoneal Chemotherapy 17 Biopsy 17

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04374630 2025-09-10

PROFECTA-II

Laekna Limited

Phase 2 Completed

Platinum-resistant Ovarian Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡